Product Search

#28047 Anti- α2, 6-Sialyltransferase (M2) Rabbit IgG Affinity Purify

  • WB
Intended Use:
Research reagents
Application:
WB
Package Size1:
100 μg
Package Size2:
10 μg
Note on Application Abbreviations
WB:Western Blotting

※ The product indicated as "Research reagents" in the column Intended Use cannot be used
  for diagnostic nor any medical purpose.
※ The datasheet listed on this page is sample only. Please refer to the datasheet
  enclosed in the product purchased before use.

Product Overview

Product Overview

Product Code 28047
Product Name Anti- α2, 6-Sialyltransferase (M2) Rabbit IgG Affinity Purify
Intended Use Research reagents
Application WB
Immunizing antigen Synthetic peptide of a part of α2, 6-sialyltransferase (NSQLVTTEKRFLKDSL) (the part common to human, mouse and rat)
Purification Method Purified with antigen peptide
Specificity Reacts with human, mouse, rat α2, 6-sialyltransferase
Package Form Lyophilized product from 1 % BSA in PBS containing 0.05 % NaN3
Storage Condition 2 - 8℃
Poisonous and Deleterious Substances Applicable
Cartagena Not Applicable
Package Size 1 100 μg
Package Size 2 10 μg
Remarks1 The commercial use of products without our permission is prohibited. Please make sure to contact us and obtain permission.

Product Description

Product Description

The histopathological picture of Alzheimer’s disease is characterized by senile plaques and neurofibrillary tangles, and because the senile plaques form first, they are considered the initial lesion. Senile plaques are known to be formed by accumulation of β-amyloid peptide (Aβ). Aβ peptide is produced by the cleavage of amyloid precursor protein (APP) by two types of proteolytic enzymes. The first cleavage is performed by β-secretase (BACE1), and the second γ-secretase. It is thought that their inhibitors may be capable of serving as safe drugs for the treatment of Alzheimer’s disease. In recent years a glycosyltransferase involved in the biosynthesis of sugar chains (α2,6-sialyltransferase) has also been shown to be cleaved by BACE1. The cleavage site was identified at the same time, and as a result it was demonstrated that in humans it produces cleavage-type α2,6-sialyltransferase (E44 Form) and in rats it produces cleavage-type α2,6-sialyltransferase (E41 Form).